The impact of converting to telehealth for cancer genetic counseling and testing during the COVID‐19 pandemic

Author:

Proussaloglou Ellie M.123ORCID,Koelliker Ekaterina L.4,Laprise Jessica5,Wilbur Jennifer Scalia5,Robison Katina126,Stuckey Ashley12,Crawford Katherine5

Affiliation:

1. Department of Obstetrics and Gynecology Women & Infants Hospital of Rhode Island Providence Rhode Island USA

2. The Warren Alpert Medical School of Brown University Providence Rhode Island USA

3. Department of Surgery Yale University New Haven Connecticut USA

4. Department of Surgery Massachusetts General Hospital Boston Massachusetts USA

5. Cancer Genetics and Prevention Program Women & Infants Hospital of Rhode Island Providence Rhode Island USA

6. Department of Obstetrics and Gynecology Tufts Medical Center Boston Massachusetts USA

Abstract

AbstractThe COVID‐19 outbreak in March 2020 resulted in a shift to telemedicine for cancer genetic counseling (GC). The objective of this study was to determine the effect of telehealth (TH) services on patient acceptance of recommended genetic testing, time to test completion, and follow‐up test‐disclosure GC appointment, as well as compliance with National Comprehensive Cancer Network (NCCN) recommendations for medical screenings when testing positive for a genetic variant. Data for this retrospective cohort study were collected at a tertiary‐care academic health center using the electronic medical record and laboratory portal. Patients with traditional in‐person visits (the 2019 control group) and date‐matched TH visits (2020) were compared. In total, 206 new GC appointments occurred in the in‐person group and 184 new appointments occurred in the TH group. The in‐person group was more likely to consent to testing than the TH cohort (92.6% vs. 82.1%, p = 0.003) and had increased rates of sample submission (99.5% vs. 93.75%, p < 0.01), as well as a shorter turn‐around time between their initial appointment and laboratory result reporting (34.24 vs. 20.32 days, p < 0.01). There was no increase in time from initial to follow‐up GC appointments (67.87 days for control, 62.39 days for THs, p = 0.37). With >2.5 years of follow‐up for all study participants, there were no statistically significant differences in pathogenic variant (PV) carrier compliance with screening recommendations. During the COVID‐19 pandemic, use of TH allowed patients to access GC with no significant differences in time between initial consultation and follow‐up. However, in‐person visits were associated with increased patient willingness to consent to and complete genetic testing. This work offers a nuanced look at the success of TH GC during the pandemic and follow‐up with screening recommendations, while offering future opportunities to address the acceptance of testing as GC is practiced in a virtual or hybrid model.

Publisher

Wiley

Subject

Genetics (clinical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3